Why pharma is still far from a treatment for galactosemia
With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are low.
Mandatory drug stock monitoring empowers EU to tackle shortages
Exelixis focuses on future growth despite COSMIC-313 trial challenges
Zevra sells priority review voucher for $150m to support drug launches
UK M&A activity down in January amid uncertain US opportunities
Inborn errors of metabolism elicit unique challenges for therapy development
Analysis
View More
Themes
View MoreScientists develop largest ever biological AI model that ‘thinks in nucleotides’
The AI neural network will help advance understanding of diseases and whole genomes.
More themes
Data Insights
View MoreCell & gene therapy: the leading companies in recombinant AAV gene therapy revealed
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Discover Data Insights powered by our proprietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
GlobalData Reports
View More
1 of 2
Digital Magazine
View MorePharma Technology Focus
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Amazon joins forces with Memorial Sloan Kettering for AI-powered drug discovery
UK awards £82.6m to AI drug discovery companies
The AI advantage in discovering new medicines
AI’s potential in women’s health exciting, says Gates Foundation leader